This blog is another installment in a series, Innovations Advanced by M&A, that underscores the unique role of mergers and acquisitions in promoting a competitive and innovative life sciences ecosystem for patients. You can find previous blogs in this series here.
In America’s life sciences industry, mergers and acquisitions (M&A) serve as a vital bridge, helping to connect promising therapies with the resources needed to turn them into approved medicines for patients. Merck’s 2021 acquisition of Acceleron Pharma is one example of how these partnerships can help bring new treatments to market and support continued innovation.
Boston-based Acceleron was founded in 2003 with specialized expertise in growth factors that were initially used to help treat metabolic disorders like obesity and diabetes. This science led to a promising approach to treat pulmonary arterial hypertension (PAH). PAH is a rare, progressive and life-threatening condition in which the small arteries in the lungs narrow, increasing blood pressure in the lungs and potentially leading to right heart failure and death. If left untreated, average survival for patients living with PAH is just two to three years.
For rare diseases like PAH, identifying and reaching the small group of patients who may benefit from a new treatment often presents distinct challenges for innovative life sciences companies. Successfully delivering a new treatment to these patients requires sophisticated regulatory, manufacturing and commercial capabilities.
As Acceleron entered Phase 3 development in 2021, the company was acquired by Merck – bringing together Acceleron’s specialized scientific expertise with Merck’s established commercial capabilities for cardiovascular therapies. This included what ultimately became Winrevair, the first FDA-approved activin-signaling inhibitor, which introduced a new class of PAH treatment that could slow or reduce disease progression.
“Acceleron’s innovative research has yielded an exciting late-stage candidate that complements and strengthens our growing cardiovascular portfolio and pipeline and holds the potential to build upon Merck’s proud legacy in cardiovascular disease.” – Rob Davis, CEO and President, Merck
Following Winrevair’s approval, Merck leveraged its established infrastructure to bring this therapy to patients across the country.
“We believe Merck is well-positioned to apply its industry-leading clinical and commercial capabilities to harness the potential of sotatercept as we join together to help make an impact on cardiopulmonary disease for the benefit of patients.” – Habib Dable, President and CEO, Acceleron
Merck has continued robust development of the treatment after its initial approval to reach more patients in need. In October 2025, the FDA updated Winrevair’s indication based on further clinical trials, recognizing the medicine’s ability to reduce events including hospitalization for PAH, lung transplantation and death. Further research is also exploring sotatercept in other difficult-to-treat conditions – including the prevention of a rare type of heart failure.
This example illustrates the unique and fundamental role of life sciences M&A in pairing pioneering science with the resources required to bring it to patients and pursue additional breakthroughs. As policymakers consider decisions affecting competition in the life sciences, it is vital they recognize and preserve the role of pro-competitive partnerships in sustaining America’s leadership in life sciences innovation.